Our programs combine best-in-class drugs with precision insights that enable first-in-class therapies to serve patients across multiple cancer indications.

Our monoclonal antibodies target secondary immune checkpoints that regulate myeloid-dependent suppression of the immune system. These antibodies have demonstrated profound efficacy accompanied by modulation of the tumor immune microenvironment in multiple solid tumor settings.

Our biomarkers for patient selection are based on unique insights from human patients that define the dynamic response of the immune system in patients who do not benefit from existing therapies.